Document text
Principal Investigator: Meghan Chenoweth
Organization: CENTRE FOR ADDICTION AND MENTAL HEALTH
Fiscal Year: 2024
Award: $144,521
Funding agency: National Institute on Drug Abuse
Project Summary
Substance use and other psychiatric disorders result in enormous personal, healthcare, and economic
costs. Substance use (e.g., tobacco use disorder) and psychiatric (e.g., schizophrenia) disorders are highly
comorbid. Three main theories have been proposed to explain the high comorbidity of tobacco use and
schizophrenia: 1) self-medication (e.g., schizophrenia promotes tobacco use due to nicotine’s effect on reducing
cognitive deficits and medication side effects), 2) tobacco use causes schizophrenia, and 3) a shared liability,
due to shared genetic and environmental factors. Tobacco use and schizophrenia are each highly heritable (~60-
80%) and we and others have shown that they share several common genetic risk factors. Two traits may share
genetic risk factors due pleiotropy (i.e., a gene variant influences both traits) or because one disorder causes
the other. Furthermore, shared genetic risk may be present in all individuals (i.e., whole-group pleiotropy) or may
be restricted to a subset of individuals (i.e., sub-group heterogeneity).
Using our expertise in tobacco use, biomarkers, schizophrenia, statistical genetics, and transcriptional
analyses, we will develop a comprehensive analytic pipeline to elucidate the shared genomic liability of tobacco
use and schizophrenia, and identify potential causal effects. Our study improves upon initial cross-disorder
analyses, and involves 1) obtaining data from the largest available genomics datasets of schizophrenia and
tobacco use, 2) examining genetic correlation between the traits, 3) identifying shared genetic variants, 4)
examining biological (i.e., mechanistic) pathways, 5) exploring functional effects of the shared genetic variants,
and 6) testing causal directions and effects of whole-group pleiotropy versus sub-group heterogeneity. In Aim 1,
we will become proficient in all 6 steps of the analytic pipeline by analyzing women and men together. In Aim 2,
we will conduct genome-wide sex-based analyses of tobacco use to determine the feasibility of using sex-based
genomic analyses in future investigations of concurrent psychiatric disorders. To develop the pipeline, we will
use nicotine intake biomarkers, which capture tobacco use more accurately than self-reported measures.
However, GWAS of self-reported traits or diagnostic criteria could be used when biomarkers are unavailable.
This grant will train the young investigator PI for a larger genomics program investigating the shared
genomic liability and causality between other pairs of heritable and concurrent psychiatric disorders. We will
apply this pipeline to diverse populations as the datasets become available. Through these efforts, we will better
understand the biological vulnerability to developing co-occurring substance use and psychiatric disorders. This
work may lead to improved prevention and treatment approaches, as well as reveal novel targets for drug
discovery.
Terms: <3'-hydroxycotinine><Address><Antipsychotic Agents><Antipsychotic Drugs><Antipsychotics><Big Data><BigData><Biologic Factor><Biological><Biological Factors><Biological Markers><Causality><Cell Communication and Signaling><Cell Signaling><Chemical Dependence><Cigarette><Cognitive deficits><Collaborations><Complex><Controlled Study><Cotinine><Data><Data Set><Differences between sexes><Differs between sexes><Disease><Disorder><Drug Addiction><Drug Dependence><Drug Dependency><Drug abuse><Drugs><Early Intervention><Environmental Factor><Environmental Risk Factor><Etiology><European ancestry><Future><GWA study><GWAS><Gene Cluster><Gene Transcription><Gene variant><Genes><Genetic><Genetic Risk><Genetic Transcription><Genetic predisposing factor><Genetic study><Genomics><Genotype><Grant><Health Care Costs><Health Costs><Healthcare Costs><Hereditary Disease><Heritability><Heterogeneity><Inborn Genetic Diseases><Individual><Inherited disorder><Intake><International><Intervention><Intervention Strategies><Intracellular Communication and Signaling><Investigation><Investigators><Major Tranquilizers><Major Tranquilizing Agents><Maps><Measures><Medication><Mendelian randomization><Mental disorders><Mental health disorders><Neuroleptic Agents><Neuroleptic Drugs><Neuroleptics><Nicotine><Nicotinic Acetylcholine Receptors><Nicotinic Receptors><Pathway interactions><Patient Self-Report><Pharmaceutical Preparations><Population><Population Heterogeneity><Prevention><Psychiatric Disease><Psychiatric Disorder><RNA Expression><Research><Research Design><Research Personnel><Researchers><Risk-associated variant><Sample Size><Schizophrenia><Schizophrenic Disorders><Scotine><Self Medication><Self-Report><Sex Differences><Sexual differences><Signal Transduction><Signal Transduction Systems><Signaling><Smoke><Smoker><Smoking><Smoking Behavior><Study Type><Subgroup><Substance Use Disorder><Testing><Tobacco Consumption><Tobacco Use Disorder><Tobacco use><Training><Transcription><Woman><Work><abuse of drugs><abuses drugs><addiction><addictive disorder><allele variant><allelic variant><bio-informatics tool><bio-markers><bioinformatics tool><biologic><biologic marker><biological signal transduction><biomarker><care costs><causation><co-morbid><co-morbidity><cognitive defects><comorbidity><comparing females and males><comparing women and men><dementia praecox><diagnostic criteria><disease causation><diverse populations><drug discovery><drug/agent><economic cost><environmental risk><experience><females compared to males><females compared with males><females versus males><females vs males><gene locus><genetic architecture><genetic locus><genetic risk factor><genetic variant><genome scale><genome wide association><genome wide association scan><genome wide association studies><genome wide association study><genome-wide><genomewide><genomewide association scan><genomewide association studies><genomewide association study><genomic data><genomic data-set><genomic dataset><genomic location><genomic locus><genomic variant><global gene expression><global transcription profile><hereditary disorder><heritable disorder><heterogeneous population><hydroxycotinine><improved><inborn error><inherited diseases><inherited factor><inherited genetic disease><inherited genetic disorder><interventional strategy><men><mental illness><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><nicotine consumption><nicotine use><non-smoker><nonsmoker><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathway><pleiotropic effect><pleiotropism><pleiotropy><population diversity><programs><psychiatric illness><psychological disorder><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><schizophrenia risk><schizophrenic><sex><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><side effect><statistics><study design><substance use><substance use and disorder><substance using><theories><tobacco disorder><tobacco product use><trait><transcriptome><treatment strategy><whole genome association analysis><whole genome association studies><whole genome association study><women compared to men><women compared with men><women versus men><women vs men>